

# ForwardHealth Covered Outpatient Drug Reimbursement

	Current Reimbursement	Proposed Reimbursement	Estimated Fiscal
<b>Brand Drugs—Ingredient Pricing Methodology</b>	Wholesale Acquisition Cost (WAC) +2	National Average Drug Acquisition Cost (NADAC), WAC +0%	-\$60,300,000
<b>Generic Drugs—Ingredient Pricing Methodology</b>	WAC -3.8% or State Maximum Allowable Cost (SMAC)	NADAC, WAC +0%	
<b>Professional Dispensing Fee</b>	<ul style="list-style-type: none"> <li>• Brand: \$3.44</li> <li>• Generic: \$3.94</li> </ul>	Tiered by annual prescription volume (all payers) of the pharmacy: <ul style="list-style-type: none"> <li>• 0-32,999: \$21.03</li> <li>• 33,000-65,999: \$13.95</li> <li>• 66,000-98,999: \$9.94</li> <li>• 99,000 or more: \$9.50</li> </ul>	\$93,700,000
<b>Specialty Drugs—Ingredient Pricing Methodology</b>	WAC +/-% rate set by market prices. Updated monthly.	Same methodology for most drugs. Some drugs will move to NADAC as a result of an updated specialty definition.  WAC +/-% rate set by market prices.	The fiscal impact is included above in the overall NADAC ingredient pricing impact.
<b>Specialty Drugs— Dispensing Fee</b>	<ul style="list-style-type: none"> <li>• Brand: \$3.44</li> <li>• Generic: \$3.94</li> </ul>	Tiered by annual prescription volume (all payers) of the pharmacy: <ul style="list-style-type: none"> <li>• 0-32,999: \$21.03</li> <li>• 33,000-65,999: \$13.95</li> <li>• 66,000-98,999: \$9.94</li> <li>• 99,000 or more: \$9.50</li> </ul>	\$700,000
<b>340B Covered Entities Using 340B Stock for Medicaid (Carve-In)— Ingredient Pricing Methodology</b>	Bill Usual and Customary (U/C) cost or Average Acquisition Cost (AAC)	Lower of ceiling price or submitted cost, WAC -50%	The fiscal impact is included above in the overall NADAC ingredient pricing impact.

	Current Reimbursement	Proposed Reimbursement	Estimated Fiscal
<b>340B—Dispensing Fee</b>	<ul style="list-style-type: none"> <li>Brand: \$3.44</li> <li>Generic: \$3.94</li> </ul>	Tiered by annual prescription volume (all payers) of the pharmacy: <ul style="list-style-type: none"> <li>0-32,999: \$21.03</li> <li>33,000-65,999: \$13.95</li> <li>66,000-98,999: \$9.94</li> <li>99,000 or more: \$9.50</li> </ul>	The fiscal impact is included above in the professional dispensing fee impact.
<b>Repackaging Allowance</b>	\$.015 per unit	Included in tiered professional dispensing fee	-\$1,500,000
<b>Compound Drugs—Ingredient Pricing</b>	Brand: \$3.44	NADAC, WAC +0%	-\$600,000
<b>Compound Drugs—Dispensing Fee</b>	\$9.45–\$22.16	Tiered by annual prescription volume (all payers) of the pharmacy: <ul style="list-style-type: none"> <li>0-32,999: \$21.03</li> <li>33,000-65,999: \$13.95</li> <li>66,000-98,999: \$9.94</li> <li>99,000 or more: \$9.50</li> </ul> A compounding add-on will be determined at a later date.	TBD
<b>Medication Therapy Management (MTM) Intervention-Based Services (Early Refill, Dose Changes)</b>	\$10.00 or \$30.00	Included in tiered professional dispensing fee	-\$800,000
<b>MTM Comprehensive Medication Review and Assessments (CMR/A)</b>	<ul style="list-style-type: none"> <li>Initial CMR/A: \$75.00</li> <li>Follow-up CMR/A: \$35.00</li> </ul>	<ul style="list-style-type: none"> <li>Initial CMR/A: \$75.00</li> <li>Follow-up CMR/A: \$35.00</li> </ul>	\$0
<b>Diabetic Supplies—Ingredient Pricing Methodology</b>	WAC + 2% (preferred products)	WAC + 2% (preferred products)	\$0
<b>Diabetic Supplies—Dispensing Fee</b>	<ul style="list-style-type: none"> <li>Brand: \$3.44</li> <li>Generic: \$3.94</li> </ul>	<ul style="list-style-type: none"> <li>Brand: \$3.44</li> <li>Generic: \$3.94</li> </ul>	
<b>Provider-Administered Drugs</b>	Average sales price (ASP) +6%	ASP +6%	\$0
<b>Administration Fee</b>	Medical billing	Medical billing	
<b>Total Estimated Fiscal Impact: \$31,200,000</b>			

